{"id":1686,"date":"2025-05-29T11:41:19","date_gmt":"2025-05-29T09:41:19","guid":{"rendered":"https:\/\/effik.ch\/hcp\/?page_id=1686"},"modified":"2025-11-10T17:06:31","modified_gmt":"2025-11-10T15:06:31","slug":"teglutik","status":"publish","type":"page","link":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/","title":{"rendered":"Teglutik"},"content":{"rendered":"<div id=\"block_51d43ef2c0fb495a49b1597e96368578\" class=\"hero-block alignfull\" style=\"background-image: url(https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/03\/amyotrophe.jpg)\">\n\t<div class=\"wrap\">\n\t\t\t\t<h1 class=\"entry-title\">Teglutik<sup>\u00ae<\/sup><\/h1>\n\t\t\t<\/div>\n<\/div>\n\n\n<div id=\"block_e8db9b2cabea8cf761f9f06eb25ddbf2\" class=\"secondary-menu-block alignfull\" style=\"\">\n<ul class=\"secondary-menu-container\">\n\t\t\t<li class=\"secondary-menu-item\">\n\t\t\t<a class=\"secondary-menu-item__content\" href=\"#teglutik\">Teglutik<sup>\u00ae<\/sup><\/a>\n\t\t<\/li>\n\t\t\t\t<li class=\"secondary-menu-item\">\n\t\t\t<a class=\"secondary-menu-item__content\" href=\"#notice\">Notice d\u2019utilisation<\/a>\n\t\t<\/li>\n\t\t\t<\/ul>\n\t<\/div>\n\n\n<div id=\"block_7765298400427f11768069052f5084c7\" class=\"inner-hero-block product-img-vertical-85 alignfull hero-mbl-column\" style=\"background-image: url(https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/03\/teglutik-bg.svg)\">\n<div class=\"anchor-div\"><\/div>\n\n\t\t\t<div class=\"inner-hero-bg-mbl\" style=\"background-image: url(https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/03\/teglutik-bg.svg); aspect-ratio:393\/200; min-height:200px;\">\n\t<div class=\"img-container\"><img loading=\"lazy\" decoding=\"async\" width=\"481\" height=\"585\" src=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/06\/Teglutik_Packshot_FR.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/06\/Teglutik_Packshot_FR.png 481w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/06\/Teglutik_Packshot_FR-247x300.png 247w\" sizes=\"auto, (max-width: 481px) 100vw, 481px\" \/><\/div>\n\t\t\t\t\t<\/div>\n\t<div class=\"wrap\" style=\"flex-direction: row-reverse;\">\n\t\t<div class=\"img-container\" style=\"justify-content: flex-end; max-height: 350px; width: calc(100% - 550px);\"><img loading=\"lazy\" decoding=\"async\" width=\"481\" height=\"585\" src=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/06\/Teglutik_Packshot_FR.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/06\/Teglutik_Packshot_FR.png 481w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2024\/06\/Teglutik_Packshot_FR-247x300.png 247w\" sizes=\"auto, (max-width: 481px) 100vw, 481px\" \/><\/div>\n\t\t\t<div class=\"content-container\" style=\"text-align: left;\">\n\t\t\t\t\t\t\t\t\t<div class=\"section-content font-medium\" style=\"max-width: 550px; align-self: flex-start;\"><p><b>La scl\u00e9rose lat\u00e9rale amyotrophique (SLA) <\/b>est une maladie neurod\u00e9g\u00e9n\u00e9rative progressive dans laquelle les cellules nerveuses responsables du contr\u00f4le musculaire et du mouvement (motoneurones) sont endommag\u00e9es.<br \/>\n&nbsp;<br \/>\n<b>L&rsquo;atrophie musculaire progressive et la perte de fonction entra\u00eenent des difficult\u00e9s croissantes de mobilit\u00e9, de parole, de d\u00e9glutition et de respiration.<\/b><\/p>\n<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n<style>\n\t.inner-hero-block {\n\t\t@media (min-width: 768px) {\n\t\taspect-ratio: 1440 \/ 350; \n\t\tmin-height: 350px;\n\t\t}\n\t}\n<\/style>\n\n\n<div id=\"hepaxane\" class=\"featured-text-block\">\n\t<div class=\"wrap\">\t\t<div class=\"featured-box\" style=\"background:#00ab5a; box-shadow:10px 10px 0px 0px rgba(0, 171, 90, 0.20);\"><h2 class=\"featured-title\">Teglutik<sup>\u00ae<\/sup>: depuis la diagnostique de SLA et adapt\u00e9 \u00e0 tous les stades de la SLA pour tous les patients<\/h2><\/div>\t<\/div>\n<\/div>\n\n\n<div id=\"teglutik\" class=\"product-content-2cols-block\" style=\"\">\n\t<div class=\"wrap\">\t\t<div class=\"product-left-content left-width-one-half\">\n\t\t\t\t\t\t\t<ul class=\"label_20_regular\">\n<li><b>Environ 600 personnes<\/b> sont <b>atteintes de SLA en Suisse<sup>1<\/sup>.<\/b><\/li>\n<li><b>Chaque ann\u00e9e, environ 200 nouvelles personnes<\/b> sont <b>diagnostiqu\u00e9es<\/b> souffrant de SLA<sup>1<\/sup>.<\/li>\n<li>La progression de la maladie peut \u00eatre tr\u00e8s diff\u00e9rente selon les personnes. <b>Environ 10-20% des patients vivent plus de 10 ans<sup>2<\/sup>.<\/b><\/li>\n<\/ul>\n\t\t\t\t\t<\/div>\n\t\t<div class=\"product-right-content left-width-one-half\">\n\t\t\t<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-large wp-image-2332\" src=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/07\/Teglutik25_web_FR-3-1024x132.png\" alt=\"\" width=\"768\" height=\"99\" srcset=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/07\/Teglutik25_web_FR-3-1024x132.png 1024w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/07\/Teglutik25_web_FR-3-300x39.png 300w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/07\/Teglutik25_web_FR-3-768x99.png 768w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/07\/Teglutik25_web_FR-3.png 1431w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/><\/p>\n\t\t<\/div>\n\t\t\t\t\t<div class=\"full-width-bottom-text\">\n\t\t\t\t<div class=\"label_20_regular pt70 border-top-blue\">\n<p>Depuis 2018, EFFIK propose <strong>Teglutik<sup>\u00ae<\/sup>, le premier Riluzole sous forme de suspension<\/strong>, d\u00e9velopp\u00e9 <strong>pour les patients atteints de SLA \u00e0 TOUS les stades de la maladie<\/strong> : d\u00e8s le diagnostic, pendant la dysphagie, jusqu&rsquo;\u00e0 l&rsquo;administration par sonde de gastrostomie (PEG).<\/p>\n<p>Le <strong>riluzole<\/strong> augmente le taux de survie des patients atteints de SLA, et ce ind\u00e9pendamment de la forme de progression primaire de la maladie (forme bulbaire ou forme p\u00e9riph\u00e9rique)<sup>4<\/sup><\/p>\n<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n<\/div>\n\n\n<div id=\"block_28d000126b6d1366c1024084e3ac7ebc\" class=\"product-content-2cols-block\" style=\"\">\n\t<div class=\"wrap\">\t\t<div class=\"product-left-content left-width-one-third\">\n\t\t\t\t\t\t\t<div class=\"h_28_700\">Vos patients b\u00e9n\u00e9ficient de Teglutik<sup>\u00ae<\/sup> depuis le d\u00e9but\u00a0du traitement et \u00e0 tous les stades de la maladie<\/div>\n\t\t\t\t\t<\/div>\n\t\t<div class=\"product-right-content left-width-one-third\">\n\t\t\t<div class=\"right-content-nocolumns pt0\"><img decoding=\"async\" class=\"alignleft size-large wp-image-1713\" src=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/Teglutik24_web_graph_1_FR-1024x373.png\" alt=\"\" width=\"100%\" height=\"auto\" srcset=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/Teglutik24_web_graph_1_FR-1024x373.png 1024w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/Teglutik24_web_graph_1_FR-300x109.png 300w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/Teglutik24_web_graph_1_FR-768x280.png 768w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/Teglutik24_web_graph_1_FR-1536x560.png 1536w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/Teglutik24_web_graph_1_FR.png 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/div>\n<div class=\"body_14_regular pt24\">Sch\u00e9ma modifi\u00e9 d\u2019apr\u00e8s Pena MJ et al. 2012<sup>5<\/sup><\/div>\n\t\t<\/div>\n\t\t\t<\/div>\n<\/div>\n\n\n<div id=\"block_05c27c853a14628e2acb3cf1af60fe80\" class=\"product-content-2cols-block\" style=\"\">\n\t<div class=\"wrap\">\t\t<div class=\"product-left-content left-width-one-third\">\n\t\t\t\t\t\t\t<div class=\"heading_32_semibold\">Teglutik<sup>\u00ae<\/sup>&#8230;<\/div>\n\t\t\t\t\t<\/div>\n\t\t<div class=\"product-right-content left-width-one-third\">\n\t\t\t<div class=\"teglutik-table-title\">D\u00e8s le diagnostic<\/div>\n<div class=\"teglutik-table\">\n<div class=\"teglutik-table-row\">\u2026apporte le bon dosage selon la tol\u00e9rance du patient<\/div>\n<div class=\"teglutik-table-row\">\u2026dispose d\u2019une forme gal\u00e9nique adapt\u00e9e pour un traitement tout au long de la maladie<\/div>\n<\/div>\n<div class=\"teglutik-table-title\">\u00c0 l\u2019apparition de la dysphagie<\/div>\n<div class=\"teglutik-table\">\n<div class=\"teglutik-table-row\">\u2026\u00e9vite de devoir piler les comprim\u00e9s de riluzole<\/div>\n<div class=\"teglutik-table-row\">\u2026\u00e9vite les fausses-routes<\/div>\n<div class=\"teglutik-table-row\">\u2026\u00e9vite l\u2019interruption th\u00e9rapeutique<\/div>\n<div class=\"teglutik-table-row\">\u2026\u00e9vite le frein du changement de forme gal\u00e9nique<\/div>\n<div class=\"teglutik-table-row\">\u2026garantit le bon dosage<\/div>\n<div class=\"teglutik-table-row\">\u2026\u00e9vite le sentiment de d\u00e9faite face \u00e0 la maladie<\/div>\n<\/div>\n<div class=\"teglutik-table-title\">\u00c0 la pose de la sonde PEG<\/div>\n<div class=\"teglutik-table\">\n<div class=\"teglutik-table-row\">\u2026\u00e9vite de devoir piler les comprim\u00e9s de riluzole<\/div>\n<div class=\"teglutik-table-row\">\u2026garantit le bon dosage<\/div>\n<div class=\"teglutik-table-row\">\u2026facilite l\u2019administration<\/div>\n<div class=\"teglutik-table-row\">\u2026\u00e9vite l\u2019obstruction de la sonde<\/div>\n<div class=\"teglutik-table-row\">\u2026a la m\u00eame biodisponibilit\u00e9 que la solution administr\u00e9e par voie orale<sup>6<\/sup><\/div>\n<\/div>\n\t\t<\/div>\n\t\t\t<\/div>\n<\/div>\n\n\n<div id=\"block_e26f7eafc7432b1f3dfa2b2ec0e03def\" class=\"teglutik-feature-block\" style=\"\">\n\t<div class=\"wrap\">\n\t\t<div class=\"feature-columns-container\"><div class=\"item\"><div class=\"left-col\">Dosage<\/div><div class=\"center-col\"><p><b>2 \u00d7 par jour 10 ml TEGLUTIK<sup>\u00ae<\/sup><\/b><\/p>\n<p>10 ml contient 50 mg Riluzole<\/p>\n<\/div><\/div><div class=\"item\"><div class=\"left-col\">Mode d\u2019administration simple et pratique<\/div><div class=\"center-col\"><p>Pr\u00eat \u00e0 l\u2019emploi \u2013 pas besoin de piler et de mettre en solution<\/p>\n<p>Dosage pr\u00e9cis gr\u00e2ce \u00e0 sa seringue gradu\u00e9e de 10 ml<\/p>\n<p>Pr\u00e9l\u00e8vement simplifi\u00e9 gr\u00e2ce \u00e0 l\u2019adaptateur int\u00e9gr\u00e9<\/p>\n<\/div><\/div><div class=\"item\"><div class=\"left-col\">D\u00e9tails du produit<\/div><div class=\"center-col\"><p><b>Concentration : <\/b>50 mg\/10 ml<b>\u00a0<\/b><\/p>\n<p><b>Forme pharmaceutique : <\/b>suspension orale<b>\u00a0<\/b><\/p>\n<p><b>Taille de l&#8217;emballage : <\/b>300 ml<b>\u00a0<\/b><\/p>\n<p><b>Dur\u00e9e de conservation : <\/b>3 ans, apr\u00e8s ouverture 15 jours<b>\u00a0<\/b><\/p>\n<p><b>Stockage : <\/b>Ne pas conserver au-dessus de 30 \u00b0C.<\/p>\n<\/div><\/div><\/div><div class=\"right-col\"><img loading=\"lazy\" decoding=\"async\" width=\"455\" height=\"485\" src=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/teglutik-1.png\" class=\"right-img\" alt=\"\" srcset=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/teglutik-1.png 455w, https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/teglutik-1-281x300.png 281w\" sizes=\"auto, (max-width: 455px) 100vw, 455px\" \/><\/div>\t<\/div>\n<\/div>\n\n\n<div id=\"block_5b12eba98e0033818ed820e4c213a405\" class=\"effilevo-block\" style=\"\">\n\t<div class=\"wrap\">\n\t\t<div id=\"product\" class=\"product-box-container\"><div class=\"product-info\"><\/div><\/div><div id=\"notice\" class=\"leaflet-container\"><div class=\"leaflet-item\"><div class=\"leaflet-title\">Information professionnelle abr\u00e9g\u00e9e Teglutik<sup>\u00ae<\/sup> (suspension buvable contenant 50\u202fmg de riluzole pour 10\u202fml). \u00a0\r\n<\/div><a class=\"blue-button\" href=\"https:\/\/effik.ch\/hcp\/wp-content\/uploads\/sites\/2\/2025\/05\/RCP_Teglutik_FR.pdf\">T\u00e9l\u00e9charger ici<\/a><\/div><div class=\"disclaimer\"><p><b>POUR DE PLUS AMPLES INFORMATIONS, CONSULTER L\u2019INFORMATION PROFESSIONNELLE SUR <\/b><u><b><i><a href=\"https:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">WWW.SWISSMEDICINFO.CH<\/a><\/i><\/b><\/u><b>.\u00a0<\/b><\/p>\n<p><b>Titulaire de l\u2019autorisation\u202f: EFFIK SA, 1260 NYON. <\/b><\/p>\n<\/div><\/div><div class=\"references\"><p>1. Schweikert, K. Scl\u00e9rose lat\u00e9rale amyotrophique. Swiss Medical Forum 2015, 15(46), 1068-1073.<br \/>\n2. Chi\u00f2 A, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5-6):310-323. doi:10.3109\/17482960802566824.<br \/>\n3. Onesti E. et al. Dysphagia in Amyotrophic Lateral Sclerosis: Impact on patient behavior, diet adaptation, and riluzole management. Front. Neurol. 8:94. doi: 10.3389\/fneur.2017.00094.<br \/>\n4. Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017 May 29;7:61-70.<br \/>\n5. Pena MJ et al. What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2012 Oct;13(6):550-4.<br \/>\n6. Brooks BR et al. Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Clin Ther. 2019 Dec;41(12):2490-2499.<\/p>\n<\/div>\t<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":1228,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":{"2":"type-page","4":"hentry"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Teglutik - EFFIK HCP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teglutik - EFFIK HCP\" \/>\n<meta property=\"og:url\" content=\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/\" \/>\n<meta property=\"og:site_name\" content=\"EFFIK HCP\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T15:06:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/\",\"url\":\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/\",\"name\":\"Teglutik - EFFIK HCP\",\"isPartOf\":{\"@id\":\"https:\/\/effik.ch\/hcp\/fr\/#website\"},\"datePublished\":\"2025-05-29T09:41:19+00:00\",\"dateModified\":\"2025-11-10T15:06:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/effik.ch\/hcp\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teglutik\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/effik.ch\/hcp\/fr\/#website\",\"url\":\"https:\/\/effik.ch\/hcp\/fr\/\",\"name\":\"EFFIK HCP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/effik.ch\/hcp\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teglutik - EFFIK HCP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/","og_locale":"fr_FR","og_type":"article","og_title":"Teglutik - EFFIK HCP","og_url":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/","og_site_name":"EFFIK HCP","article_modified_time":"2025-11-10T15:06:31+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/","url":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/","name":"Teglutik - EFFIK HCP","isPartOf":{"@id":"https:\/\/effik.ch\/hcp\/fr\/#website"},"datePublished":"2025-05-29T09:41:19+00:00","dateModified":"2025-11-10T15:06:31+00:00","breadcrumb":{"@id":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/effik.ch\/hcp\/fr\/neurologie\/sclerose-laterale-amyotrophique\/teglutik\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/effik.ch\/hcp\/fr\/"},{"@type":"ListItem","position":2,"name":"Teglutik"}]},{"@type":"WebSite","@id":"https:\/\/effik.ch\/hcp\/fr\/#website","url":"https:\/\/effik.ch\/hcp\/fr\/","name":"EFFIK HCP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/effik.ch\/hcp\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/pages\/1686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/comments?post=1686"}],"version-history":[{"count":28,"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/pages\/1686\/revisions"}],"predecessor-version":[{"id":2529,"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/pages\/1686\/revisions\/2529"}],"up":[{"embeddable":true,"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/pages\/1228"}],"wp:attachment":[{"href":"https:\/\/effik.ch\/hcp\/fr\/wp-json\/wp\/v2\/media?parent=1686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}